Advertisement

Bispezifische Antikörper — Werkzeuge zur T-Zell Rekrutierung

  • Heribert Bohlen
  • Oliver Manzke
  • Hans Tesch
Part of the Handbuch der Molekularen Medizin book series (HDBMOLEK, volume 2)

Zusammenfassung

Seit der Entdeckung monoklonaler Antikörper durch Köhler u. Milstein [1975] werden diese in einer Vielzahl von Therapieversuchen eingesetzt [Brennan et al. 1985, Paulus 1985]. Bispezifische Antikörper bilden eine neue Generation von Antikörpern und erkennen im Gegensatz zu herkömmlichen Antikörpern 2 unterschiedliche Antigene. Sie lassen sich aufgrund dieser Eigenschaft vielfältig in der Tumortherapie einsetzen [Staerz u. Bevan 1986].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alkan SS, Towbin H, Hochkeppel HK (1988) Enhanced antiproliferative action of interferon targeted by bispecific monoclonal antibodies. J Interferon Res 8: 25–33PubMedCrossRefGoogle Scholar
  2. Anderson PM, Crist W, Hasz D, Carroll AJ, Myers DE, Uckun FM (1992) G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD 19 antigen-specific lysis of t(4; 11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 80: 2826–2834PubMedGoogle Scholar
  3. Assoc JAO, Koulova L, Clark EA, Shu G, Dupont B (1991) The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med Behav Res Ther 173: 759–762Google Scholar
  4. Azuma A, Niitani H, Okumura K (1991) [Cancer therapy by using bispecific antibody]. Gan To Kagaku Ryoho 18: 1535–1542PubMedGoogle Scholar
  5. Azuma M, Phillips JH, Lanier LL (1992) CD28 co-stimulation of T-cell-mediated cytotoxicity. Int J Cancer Suppl 7: 33–35PubMedGoogle Scholar
  6. Ball ED, Guyre PM, Mills L, Fisher J, Dinces NB, Fanger MW (1992) Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD 15 (Mb PM81) and anti-CD64/Fc gamma RI (Mb 32). J Hematother 1: 85–94PubMedCrossRefGoogle Scholar
  7. Blum S, Milesi R, Tratkiewicz J, Olive D, Gallati H, Cerottini JC, Fliedner V von (1994) Rapid induction of cytolytic T cells via CD28 stimulation for cellular immunotherapy. Ther Immunol 1: 143–152PubMedGoogle Scholar
  8. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickra-manayake PD, Diehl V, Tesch H (1993a) Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD 19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82: 1803–1812PubMedGoogle Scholar
  9. Bohlen H, Manzke 0, Patel B, Moldenhauer G, Dorken B, Fliedner V von, Diehl V, Tesch H (1993b) Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 53: 4310–4314PubMedGoogle Scholar
  10. Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB, Stoter G, Lanzavecchia A, Re E di, Miotti S, Raspa-gliesi F et al. (1992) Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multi-center study. Int J Cancer Suppl 7: 78–81PubMedGoogle Scholar
  11. Bonardi MA, Bell A, French RR, Gromo G, Hamblin T, Modena D, Tutt AL, Glennie MJ (1992) Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Int J Cancer Suppl 7: 73–77PubMedGoogle Scholar
  12. Brennan M, Daviso PF, Paulus H (1985) Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229: 81–83PubMedCrossRefGoogle Scholar
  13. Brissinck J, Demanet C, Moser M, Leo O, Thielemans K (1991) Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol 147: 4019–4026PubMedGoogle Scholar
  14. Bruynck A, Seemann G, Bosslet K (1993) Characterisation of a humanised bispecific monoclonal antibody for cancer therapy. Br J Cancer 67: 436–440PubMedCrossRefGoogle Scholar
  15. Chervonsky AV, Faerman Al, Evdonina LV, Jazova AK, Kazarov AR, Gussev Al (1988) A simple metabolic system for selection of hybrid hybridomas (tetradomas) producing bispecific monoclonal antibodies. Mol Immunol 25: 913–915PubMedCrossRefGoogle Scholar
  16. Damle NK, Linsley PS, Ledbetter JA (1991) Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7. Eur J Immunol 21: 1277–1282PubMedCrossRefGoogle Scholar
  17. De Gast GC, Haagen IA, Van Houten AA, Klein SC, Duits AJ, De Weger RA, Vroom TM, Clark MR et al. (1995a) CD8 T cell activation after intravenous administration of CD3*CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40: 390–396PubMedCrossRefGoogle Scholar
  18. De Gast GC, Van Houten AA, Haagen IA, Klein S, De Weger RA, Van Dijk A, Phillips J, Clark M, Bast BJ (1995b) Clinical experience with CD3*CD 19 bispecific antibodies in patients with B cell malignancies. J Hematother 4: 433–437PubMedCrossRefGoogle Scholar
  19. De Lau WB, Heije K, Neefjes JJ, Oosterwegel M, Rozemuller E, Bast BJ (1991) Absence of preferential homologous H/ L chain association in hybrid hybridomas. J Immunol 146: 906–914PubMedGoogle Scholar
  20. Engert A, Pohl C, Diehl V (1992) Experimental therapy in Hodgkin’s disease. Ann Oncol 4: 97–100Google Scholar
  21. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M (1994) Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24: 605–610PubMedCrossRefGoogle Scholar
  22. French RR, Courtenay AE, Ingamells S, Stevenson GT, Glennie MJ (1991) Cooperative mixtures of bispecific F(ab’)2 antibodies for delivering saporin to lymphoma in vitro and in vivo. Cancer Res 51: 2353–2361PubMedGoogle Scholar
  23. French RR, Hamblin TJ, Bell AJ, Tutt AL, Glennie MJ (1995) Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin. Lancet 346: 223–224PubMedCrossRefGoogle Scholar
  24. George AJT, Titus JA, Jost CR, Kurucz I, Perez P, Andrew SM, Nicholls PJ, Huston JS, Segal DM (1994) Redirection of T-cell mediated cytotoxicity by a recombinant single chain Fv molecule. J Immunol 152: 1802–1811PubMedGoogle Scholar
  25. Geppert TD, Lipsky PE (1988) Activation of T lymphocytes by immobilized monoclonal antibodies to CD3. Regulatory influences of monoclonal antibodies to additional T cell surface determinants. J Clin Invest 81: 1497–1505PubMedCrossRefGoogle Scholar
  26. Gilliland LK, Clark MR, Waldmann H (1988) Universal bi specific antibody for targeting tumor cells for destruction by cytotoxic T cells. Proc Natl Acad Sci USA 85: 7719–7723PubMedCrossRefGoogle Scholar
  27. Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, Mafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC, Hoogenboom HR, Winter G (1993) Human anti-self antibodies with high specificity from phage display libraries. EMBO J 12: 725–734PubMedGoogle Scholar
  28. Gruber M, Schodin BA, Wilson ER, Kranz DM (1994) Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol 152: 5368–5374PubMedGoogle Scholar
  29. Haagen IA (1995) Performance of CD3xD19 bispecific monoclonal antibodies in B cell malignancy. Leuk Lymphoma 19: 381–393PubMedCrossRefGoogle Scholar
  30. Haagen IA, Geerars AJ, Lau WB de, Clark MR, Griend RJ van de, Bast BJ, Gast BC de (1994) Killing of autologous B-lineage malignancy using CD3*CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 84: 556–563PubMedGoogle Scholar
  31. Harding FA, Allison JP (1993) CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 177: 1791–1796PubMedCrossRefGoogle Scholar
  32. Holliger P, Winter G (1993) Engineering bispecific antibodies. Curr Opin Biotechnol4: 446–449Google Scholar
  33. Holliger P, Prospero T, Winter G (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90: 6444–6448PubMedCrossRefGoogle Scholar
  34. Hoogenboom HR, Winter G (1992) By-passing immunisation: human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 227: 381–388PubMedCrossRefGoogle Scholar
  35. Hoogenboom HR, Marks JD, Griffiths AD, Winter G (1992) Building antibodies from their genes. Immunol Rev 130: 41–68PubMedCrossRefGoogle Scholar
  36. Inaba K, Inaba M, Naito M, Steinman RM (1993) Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med 178: 479–488PubMedCrossRefGoogle Scholar
  37. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Taylor WJ, Freedman RS (1993) Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. Scand J Immunol 37: 413–424PubMedCrossRefGoogle Scholar
  38. Jung G, Eberhard HJ (1988) An in-vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol Today 9: 257–260PubMedCrossRefGoogle Scholar
  39. Jung G, Ledbetter JA, Muller-Eberhard HJ (1987) Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sci USA 84: 4611–4615PubMedCrossRefGoogle Scholar
  40. Kaneko T, Fusauchi Y, Kakui Y, Masuda M, Akahoshi M, Teramura M, Motoji T, Okumura K, Mizoguchi H, Oshimi K (1993) A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. Blood 81: 1333–1341PubMedGoogle Scholar
  41. Karawajew L, Micheel B, Behrsing O, Gaestel M (1987) Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter.J Immunol Methods 96: 265–270PubMedCrossRefGoogle Scholar
  42. Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O’Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA (1993) T-cell recognition of human melanoma antigens. J Immunother 14: 88–93CrossRefGoogle Scholar
  43. Kipriyanov SM, Breitling F, Little M, Dubel S (1995) Single-chain antibody streptavidin fusions: tetrameric Afunctional sv-complexes with biotin binding activity and enhanced affinity to antigen. Hum Antibodies Hybridomas 6: 93–101PubMedGoogle Scholar
  44. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497PubMedCrossRefGoogle Scholar
  45. Kroesen BJ, Haar A ter, Spakman H, Willemse P, Sleijfer DT et al. (1993) Local antitumour treatment in carcinoma patients with bispecifk-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother 37: 400–407PubMedCrossRefGoogle Scholar
  46. Kroesen BJ, Buter J, Sleijfer DT, Janssen RA, Graaf WT van der, Leji L de, Mulder NH (1994) Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 70: 652–661PubMedCrossRefGoogle Scholar
  47. Kroesen BJ, Janssen RA, Buter J, Nieken J, Sleijfer DT, Mulder NH, De Leij L (1995) Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects. J Hematother 4: 409–414PubMedCrossRefGoogle Scholar
  48. Kuppen PJ, Eggermont AM, Smits KM, Eendenburg JD van, Lazeroms SP, Velde CJ van de, Fleuren GJ (1993) The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531. Cancer Immunol Immunother 36: 403–408PubMedCrossRefGoogle Scholar
  49. Lattime EC, Gomella LG, Mue PA (1992) Murine bladder carcinoma cells present antigen to BCG-specifk CD4+ T-cells. Cancer Res 52: 4286–4290PubMedGoogle Scholar
  50. Le DJ, Gruaz GA, Martin M, Gautherot E, Delaage M, Barbet J (1990) Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice [published erratum appears in Cancer Res 1990 50: 6115]. Cancer Res 50: 3445–3452Google Scholar
  51. Le DJ, Chetanneau A, Gruaz GA, Martin M, Gautherot E, Le-hur PA, Chatal JF, Delaage M, Barbet J (1993) Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 34: 1662–1671Google Scholar
  52. Le-Doussal DJ, Barbet J, Delaage M (1992) Bispecific-anti-body-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results. Int J Cancer Suppl 7: 58–62PubMedGoogle Scholar
  53. Li Y, Mowan P, Hellstrom I, Hellstrom KE, Chen L (1994) Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153: 421–428PubMedGoogle Scholar
  54. Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11: 191–212PubMedCrossRefGoogle Scholar
  55. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R (1985) A clinical trial of antiidiotype therapy for B cell malignancy. Blood 65: 1349–1363PubMedGoogle Scholar
  56. Mezzanzanica D, Canevari S, Colnaghi MI (1991) Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. Int J Clin Lab Res 21: 159–164CrossRefGoogle Scholar
  57. Morelli D, Sardini A, Villa E, Villa ML, Menard S, Colnaghi MI, Balsari A (1994a) Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin. Cancer Immunol Immunother 38: 171–177PubMedGoogle Scholar
  58. Morelli D, Villa E, Tagliabue E, Perletti L, Villa ML, Menard S, Balsari A, Colnaghi MI (1994b) Relevance of antibody valency in EGF receptor modulation. Scand J Immunol 39: 453–458PubMedCrossRefGoogle Scholar
  59. Moreno MB, Titus JA, Cole MS, Tso JY, Le N, Paik CH, Bakacs T, Zacharchuk CM, Segal DM, Wunderlich JR (1995) Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo. Cancer Immunol Immunother 40: 182–190PubMedCrossRefGoogle Scholar
  60. Nair S, Zhou F, Reddy R, Huang L, Rouse BT (1992) Soluble proteins delivered to dendritic cells via -sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 175: 609–612PubMedCrossRefGoogle Scholar
  61. Nijhuis EW (1990) Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies. Cancer Immunol Immunother 32: 245–250PubMedCrossRefGoogle Scholar
  62. Nitta T, Sato K, Yagita H, Okumura K, Ishii S (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368–371PubMedCrossRefGoogle Scholar
  63. Nitta T, Nakata M, Yagita H, Okumura K (1991) Interleukin-2 activated T cells (T-LAK) express CD 16 antigen and are triggered to target cell lysis by bispecific antibody. Immunol Lett 28: 31–37PubMedCrossRefGoogle Scholar
  64. Oshimi K, Seto T, Oshimi Y, Masuda M, Okumura K, Mizoguchi H (1991) Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab’ antibody cross-linked to anti-CD 10 Fab’ antibody. Blood 77: 1044–1049PubMedGoogle Scholar
  65. Paulus H (1985) Preparation and biomedical applications of bispecific antibodies. Behring Inst Mitt, Germany, 78: 118–132Google Scholar
  66. Perisic O, Webb PA, Holliger P, Winter G, Williams RL (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2: 1217–1226PubMedCrossRefGoogle Scholar
  67. Pohl C, Renner C, Schwonzen M, Schobert I, Liebenberg V, Jung W, Wolf J, Pfreundschuh M, Diehl V (1993) CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin’s lymphoma. Int J Cancer 54: 418–425PubMedCrossRefGoogle Scholar
  68. Raag R, Whitlow M (1995) Single chain Fv proteins and their fusion proteins. FASEB J 9: 73–80PubMedGoogle Scholar
  69. Ravenswaay Claasen HH van, Eggermont AM, Nooyen YA, Warnaar SO, Fieuren GJ (1994) Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR. Gynecol Oncol 52: 199–206CrossRefGoogle Scholar
  70. Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, Van de Winkel JG, Lang N et al. (1995) G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). J Hematother 4: 415–421PubMedCrossRefGoogle Scholar
  71. Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V, Pfreundschuh M (1990) Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/ anti-alkaline phosphatase monoclonal antibody. Cancer Res 50: 6944–6948PubMedGoogle Scholar
  72. Sakato N, Rugdech P, Yoda T, Ota A, Zhao Y, Semma M, Suzuki Y, Fujio H (1990) Activation of idiotype-specific CD4+ T-cell line: cellular processing of exogenous self-immunoglobulin. Immunology 71: 153–157PubMedGoogle Scholar
  73. Segal DM, Sconocchia G, Titus JA, Jost CR, Kurucz I (1995) Alternative triggering molecules and single chain bispecific antibodies. J Hematother 4: 377–382PubMedCrossRefGoogle Scholar
  74. Shalaby MR, Carter P, Maneval D, Giltinan D, Kotts C (1995) Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. Clin Immunol Immunopathol 74: 185–192PubMedCrossRefGoogle Scholar
  75. Shen GL, Li JL, Vitetta ES (1994) Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing. J Immunol 152: 2368–2376PubMedGoogle Scholar
  76. Silla LM, Chen J, Zhong RK, Whiteside TL, Ball ED (1995) Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD 16 (Fc gamma RIII) expressed by human natural killer (NK) cells. Br J Haematol 89: 712–718PubMedCrossRefGoogle Scholar
  77. Somasundaram C, Matzku S, Schuhmacher J, Zoller M (1993) Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy. Cancer Immunol Immunother 36: 337–345PubMedCrossRefGoogle Scholar
  78. Sornasse T, Flamand V, De Becker G, Bazin H, Tielemans F, Thielemans K, Urbain J, Leo O, Moser M (1992) Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J Exp Med 175: 15–21PubMedCrossRefGoogle Scholar
  79. Staerz UD, Bevan MJ (1986) Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA 83: 1453–1457PubMedCrossRefGoogle Scholar
  80. Taga K, Mostowski H, Tosato G (1993) Human interleukin-10 can directly inhibit T-cell growth. Blood 81: 2964–2971PubMedGoogle Scholar
  81. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Brad-shaw J, Ledbetter JA, Linsley PS (1993) Induction of al-loantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 177: 165–173PubMedCrossRefGoogle Scholar
  82. Tarditi L, Camagna M, Parisi A, Vassarotto C, De Monte LB, Letarte M, Malavasi F, Mariani M (1992) Selective high-performance liquid chromatographic purification of bispecific monoclonal antibodies. J Chromatogr 599: 13–20PubMedCrossRefGoogle Scholar
  83. Thielemans K, Rothbard JB, Levy S, Levy R (1985) Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens. J Exp Med 162: 19–34PubMedCrossRefGoogle Scholar
  84. Traunecker A, Lanzavecchia A, Karjalainen K (1991) Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J 10: 3655–3659PubMedGoogle Scholar
  85. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Ernstoff MS, Wells W, Barth R, Deo Y, Fisher J et al. (1995) Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that over-expresses HER-2/neu. J Hematother 4: 471–475PubMedCrossRefGoogle Scholar
  86. Vitetta ES, Thorpe PE (1982) Immunotoxins. In: Vita SHRVd (ed) Biologic therapy of cancer: principles and practice. Lippincott, PhiladelphiaGoogle Scholar
  87. Warnaar SO, De Paus V, Lardenoije R, Machielse BN, De Graaf J, Bregonje M, Van Haarlem H (1994) Purification of bispecific F(ab’)2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer. Hybridoma 13: 519–526PubMedGoogle Scholar
  88. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK (1995a) Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-er-2 and Fc gamma RIII. Cancer Res 55: 4586–4593PubMedGoogle Scholar
  89. Weiner LM, Clark JI, Ring DB, Alpaugh RK (1995b) Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-er-2 and Fc gamma RIII. J Hematother 4: 453–456PubMedCrossRefGoogle Scholar
  90. Wolf H, Muller Y, Salmen S, Wilmanns W, Jung G (1994) Induction of anergy in resting human T lymphocytes by immobilized anti-CD3 antibodies. Eur J Immunol 24: 1410–1417PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Heribert Bohlen
  • Oliver Manzke
  • Hans Tesch

There are no affiliations available

Personalised recommendations